@prefix rdf: . @prefix dbr: . @prefix owl: . dbr:Multidrug-resistant_tuberculosis rdf:type owl:Thing . @prefix wikidata: . dbr:Multidrug-resistant_tuberculosis rdf:type wikidata:Q12136 . @prefix dbo: . dbr:Multidrug-resistant_tuberculosis rdf:type dbo:Disease . @prefix rdfs: . dbr:Multidrug-resistant_tuberculosis rdfs:label "TB-MDR"@es , "\u591A\u5264\u8010\u6027\u80BA\u7D50\u6838"@ja , "Tuberculose multirresistente"@pt , "Multidrug-resistant tuberculosis"@en , "Multiresistent tuberkulos"@sv , "\u0645\u0642\u0627\u0648\u0645\u0629 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0645\u0636\u0627\u062F\u0629 \u0644\u0644\u0633\u0644"@ar , "\uB2E4\uC81C\uB0B4\uC131 \uACB0\uD575"@ko ; rdfs:comment "Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampin. Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB (XDR-TB)."@en , "Tuberculose multirresistente (MDR-TB) \u00E9 uma infe\u00E7\u00E3o por tuberculose causada por bact\u00E9rias resistentes ao tratamento com pelo menos dois dos mais fortes medicamentos de primeira linha, isoniazida e rifampicina. Algumas formas de tuberculose s\u00E3o tamb\u00E9m resistentes a medicamentos de segunda linha, sendo nesse caso denominadas tuberculose extensivamente resistente (XDR-TB)."@pt , "\uB2E4\uC81C\uB0B4\uC131 \uACB0\uD575(\u591A\u5291\u8010\u6027\u7D50\u6838, MDR-TB)\uC740 \uAC00\uC7A5 \uAC15\uB825\uD55C \uACB0\uD575 \uCE58\uB8CC\uC81C\uB85C\uC11C 1\uCC28 \uC57D\uC81C\uB85C \uC4F0\uC774\uB294 \uC774\uC18C\uB2C8\uC544\uC9C0\uB4DC(Isoniazid, INH)\uC640 \uB9AC\uD31C\uD53C\uC2E0(Rifampicin, RMP)\uC5D0 \uB0B4\uC131\uC744 \uC9C0\uB2C8\uACE0 \uC788\uB294 \uACB0\uD575\uC744 \uB9D0\uD55C\uB2E4. \uB2E8, \uB2E4\uB978 \uD56D\uACB0\uD575\uC81C\uC758 \uC870\uD569\uC5D0 \uB0B4\uC131\uC774 \uC788\uB2E4\uACE0 \uD558\uB354\uB77C\uB3C4 \uC774\uC18C\uB2C8\uC544\uC9C0\uB4DC\uC640 \uB9AC\uD31C\uD53C\uC2E0\uC5D0 \uB300\uD55C \uB0B4\uC131\uC774 \uC5C6\uC73C\uBA74 \uB2E4\uC81C\uB0B4\uC131 \uACB0\uD575\uC73C\uB85C \uBD84\uB958\uB418\uC9C0 \uC54A\uB294\uB2E4. \uB2E4\uC81C\uB0B4\uC131 \uACB0\uD575\uC740 \uBAA8\uB4E0 \uC57D\uC5D0 \uB4E3\uB294 \uACB0\uD575\uC744 \uCE58\uB8CC\uD558\uB294 \uB3C4\uC911 \uD56D\uC0DD\uC81C\uC758 \uD22C\uC785\uC774 \uC911\uB2E8\uB418\uAC70\uB098 \uCCB4\uB0B4\uC758 \uC57D\uC758 \uC218\uC900\uC774 \uC138\uADE0\uC758 100%\uB97C \uC8FD\uC774\uAE30\uC5D0 \uCDA9\uBD84\uD558\uC9C0 \uC54A\uC744 \uB54C\uC5D0 \uC0DD\uACA8\uB09C\uB2E4. \uADF8 \uC774\uC720\uB85C\uB294 \uC5EC\uB7EC \uAC00\uC9C0\uAC00 \uC788\uB2E4. \uD658\uC790\uB4E4\uC740 \uBCD1\uC138\uAC00 \uD638\uC804\uB418\uC5C8\uB2E4\uACE0 \uC0DD\uAC01\uD558\uACE0 \uD56D\uC0DD\uC81C\uC758 \uD22C\uC785\uC744 \uC911\uB2E8\uD560 \uC218 \uC788\uC73C\uBA70, \uC81C\uACF5\uB418\uB358 \uC57D\uC774 \uB5A8\uC5B4\uC9C0\uAC70\uB098 \uD76C\uADC0\uD574\uC9C8 \uC218 \uC788\uACE0, \uD658\uC790\uAC00 \uAC00\uB054 \uC57D \uBA39\uB294 \uAC83\uC744 \uC78A\uC744 \uC218 \uC788\uB2E4. \uB2E4\uC81C\uB0B4\uC131 \uACB0\uD575\uC740 \uC57D\uC5D0 \uAC10\uC218\uC131\uC774 \uC788\uB294 \uACB0\uD575\uACFC \uAC19\uC740 \uBC29\uBC95\uC73C\uB85C \uC0AC\uB78C\uC5D0\uC11C \uC0AC\uB78C\uC73C\uB85C \uC804\uD30C\uB41C\uB2E4."@ko , "Multiresistent tuberkulos \u00E4r en variant av den bakteriella infektionssjukdomen tuberkulos som \u00E4r resistent mot de tv\u00E5 mest effektiva tuberkulosl\u00E4kemedel Isoniazid och Rifampicin. Internationellt anv\u00E4nds ofta begreppet multi-drug-resistant tuberculosis och d\u00E4rf\u00F6r f\u00F6rkortas sjukdomen med MDR-TB. Det finns dessutom ytterligare en form av tuberkulos som \u00E4r resistent mot \u00E4nnu fler l\u00E4kemedel och som betecknas som \u201Dextended multi-drug resistant tuberculosis\u201D eller XDR-TB."@sv , "\u591A\u5264\u8010\u6027\u80BA\u7D50\u6838\uFF08\u305F\u3056\u3044\u305F\u3044\u305B\u3044\u306F\u3044\u3051\u3063\u304B\u304F\u3001MDR\uFF09\u3068\u306F\u3001\u80BA\u7D50\u6838\u306E\u3046\u3061\u3001\u6CBB\u7642\u3068\u3057\u3066\u4F7F\u308F\u308C\u308B\u6297\u751F\u7269\u8CEA\u306E\u30A4\u30BD\u30CB\u30A2\u30B8\u30C9\u3084\u30EA\u30D5\u30A1\u30F3\u30D4\u30B7\u30F3\u306A\u3069\u306B\u85AC\u5264\u8010\u6027\u3092\u6301\u3063\u305F\u72B6\u614B\u3092\u3044\u3046\u3002"@ja , "\u0645\u0642\u0627\u0648\u0645\u0629 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0645\u0636\u0627\u062F\u0629 \u0644\u0644\u0633\u0644 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Multi-drug-resistant tuberculosis)\u200F \u0647\u0648 \u0639\u0628\u0627\u0631\u0629 \u0639\u0646 \u0638\u0647\u0648\u0631 \u0633\u0644\u0627\u0644\u0627\u062A \u0644\u0645\u0631\u0636 \u0627\u0644\u0633\u0644 \u0645\u0642\u0627\u0648\u0645\u0629 \u0644\u062C\u0645\u064A\u0639 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0631\u0626\u064A\u0633\u064A\u0629 \u0627\u0644\u0645\u0636\u0627\u062F\u0629 \u0644\u0644\u0633\u0644. \u0648\u062D\u0627\u0644\u0627\u062A \u0627\u0644\u0633\u0644 \u0627\u0644\u0645\u0642\u0627\u0648\u0645 \u0644\u0644\u0623\u062F\u0648\u064A\u0629 \u0646\u0627\u062C\u0645\u0629 \u0639\u0646 \u0627\u0644\u0639\u0644\u0627\u062C \u063A\u064A\u0631 \u0627\u0644\u0645\u0646\u0627\u0633\u0628 \u0623\u0648 \u0627\u0644\u0639\u0644\u0627\u062C \u0627\u0644\u062C\u0632\u0626\u064A\u060C \u0623\u064A \u0639\u0646\u062F\u0645\u0627 \u0644\u0627 \u064A\u0623\u062E\u0630 \u0627\u0644\u0645\u0631\u0636\u0649 \u062C\u0645\u064A\u0639 \u0623\u062F\u0648\u064A\u062A\u0647\u0645 \u0628\u0627\u0646\u062A\u0638\u0627\u0645 \u0623\u062B\u0646\u0627\u0621 \u0627\u0644\u0641\u062A\u0631\u0629 \u0627\u0644\u0645\u062D\u062F\u0651\u062F\u0629 \u0644\u0647\u0645 \u0628\u0633\u0628\u0628 \u0634\u0639\u0648\u0631\u0647\u0645 \u0628\u062A\u062D\u0633\u0646 \u062D\u0627\u0644\u062A\u0647\u0645 \u0627\u0644\u0635\u062D\u064A\u0629\u060C \u0623\u0648 \u0646\u0638\u0631\u0627\u064B \u0644\u0646\u0632\u0648\u0639 \u0627\u0644\u0623\u0637\u0628\u0627\u0621 \u0648\u0627\u0644\u0639\u0627\u0645\u0644\u064A\u0646 \u0627\u0644\u0635\u062D\u064A\u064A\u0646 \u0625\u0644\u0649 \u0648\u0635\u0641 \u062E\u0637\u0637 \u0639\u0644\u0627\u062C\u064A\u0629 \u062E\u0627\u0637\u0626\u0629\u060C \u0623\u0648 \u0646\u0638\u0631\u0627\u064B \u0644\u0639\u062F\u0645 \u0645\u0648\u062B\u0648\u0642\u064A\u0629 \u0627\u0644\u0625\u0645\u062F\u0627\u062F\u0627\u062A \u0627\u0644\u062F\u0648\u0627\u0626\u064A\u0629."@ar , "Se conoce como tuberculosis multidrogorresistente (TB-MDR) es aquella infecci\u00F3n por Mycobacterium tuberculosis por aquellas cepas de esta bacteria resistentes a los siguientes dos : \n* Isoniacida \n* Rifampicina Los primeros casos fueron detectados en brotes en los Estados Unidos y Argentina a fines de la d\u00E9cada de los 80s. Se requiere f\u00E1rmacos de segunda l\u00EDnea que son menos eficaces y con efectos adversos m\u00E1s graves. Se ha reportado una asociaci\u00F3n de casos de TB-MDR con la infecci\u00F3n por VIH y algunos estados de inmunosupresi\u00F3n."@es ; rdfs:seeAlso dbr:Tuberculosis_treatment . @prefix foaf: . dbr:Multidrug-resistant_tuberculosis foaf:name "Multidrug-resistance tuberculosis"@en . @prefix dbp: . dbr:Multidrug-resistant_tuberculosis dbp:name "Multidrug-resistance tuberculosis"@en ; foaf:depiction . @prefix dcterms: . @prefix dbc: . dbr:Multidrug-resistant_tuberculosis dcterms:subject dbc:Pharmaceuticals_policy , dbc:Antibiotic-resistant_bacteria , dbc:Tuberculosis ; dbo:wikiPageID 11321017 ; dbo:wikiPageRevisionID 1111985119 ; dbo:wikiPageWikiLink dbr:Arginine , dbr:Methicillin-resistant_Staphylococcus_aureus , dbr:National_Jewish_Medical_and_Research_Center , , dbr:Antimicrobial_resistance , dbr:DOTS , dbr:Pyrazinamide , dbr:Structural_violence_in_Haiti , , dbr:HIV-positive , dbr:Adenosine_triphosphate , dbc:Pharmaceuticals_policy , dbr:Vancomycin-resistant_enterococcus , dbc:Antibiotic-resistant_bacteria , , dbr:Woodrow_Wilson_Center , dbr:AIDS , dbr:Protein , dbr:Moldova , dbr:Enzyme , dbr:Clofazimine , dbr:Paul_Farmer , dbr:Aminoglycoside , dbr:Metronidazole , dbr:Capreomycin , dbr:Fluoroquinolones , dbr:Multidrug-resistant_tuberculosis , dbr:European_Centre_for_Disease_Prevention_and_Control , dbr:Totally-drug-resistant_tuberculosis , dbr:Tuberculosis , dbr:Extensively_drug-resistant_tuberculosis , dbr:Murray_Feshbach , dbr:Imipenem , , dbr:Drug_resistance , dbr:Medicines_Patent_Pool , dbr:Lipid , dbr:Cell_wall , dbr:Moxifloxacin , dbr:Antibiotic_resistance , dbr:Food_and_Drug_Administration , dbr:Horizontal_gene_transfer , dbr:V5_Immunitor , dbr:Ofloxacin , , dbc:Tuberculosis , dbr:Co-amoxiclav , , dbr:RpoB , dbr:Rifampicin , dbr:HIV , dbr:Pretomanid , dbr:Mycobacterium_tuberculosis , dbr:Human_rights , dbr:TB_Alliance , dbr:Prochlorperazine , dbr:University_of_California_Press , dbr:Quinolone_antibiotic , dbr:Bedaquiline , dbr:Hachette_Books , dbr:Novartis , dbr:Russian_prisons , dbr:Mutation , dbr:Therapeutic_drug_monitoring , dbr:First-line_treatment , dbr:Dzherelo , dbr:Delamanid , dbr:ATP_synthase , dbr:Plasmid , dbr:Isoniazid , dbr:Kanamycin_A , dbr:Lima , , dbr:Streptomycin , dbr:Cycloserine , dbr:Rifampin , dbr:Ethambutol , , dbr:Therapy , dbr:Vitamin_D , dbr:Tuberculosis_management , , dbr:Totally_drug-resistant_tuberculosis , dbr:Amikacin ; dbo:wikiPageExternalLink . @prefix ns10: . dbr:Multidrug-resistant_tuberculosis dbo:wikiPageExternalLink ns10:comingplaguenew000garr . @prefix ns11: . dbr:Multidrug-resistant_tuberculosis dbo:wikiPageExternalLink ns11:you-never-think-about-tuberculosis-until-you-lose-two-years , , ns10:infectionsinequa0000farm , . @prefix ns12: . dbr:Multidrug-resistant_tuberculosis dbo:wikiPageExternalLink ns12:U0000mCG87xLc654 , ns10:betrayaloftrustc00garr_0 ; owl:sameAs . @prefix dbpedia-sv: . dbr:Multidrug-resistant_tuberculosis owl:sameAs dbpedia-sv:Multiresistent_tuberkulos , , , , , wikidata:Q866602 , , . @prefix dbpedia-pt: . dbr:Multidrug-resistant_tuberculosis owl:sameAs dbpedia-pt:Tuberculose_multirresistente . @prefix dbpedia-es: . dbr:Multidrug-resistant_tuberculosis owl:sameAs dbpedia-es:TB-MDR , . @prefix dbpedia-af: . dbr:Multidrug-resistant_tuberculosis owl:sameAs dbpedia-af:Middelweerstandige_tuberkulose . @prefix dbt: . dbr:Multidrug-resistant_tuberculosis dbp:wikiPageUsesTemplate dbt:Gram-positive_actinobacteria_diseases , dbt:Reflist , dbt:Citation_needed , dbt:Who , dbt:Medical_resources , dbt:Main , dbt:Authority_control , dbt:Use_dmy_dates , dbt:Cite_book , dbt:Cn , dbt:See_also , dbt:Page_needed , dbt:Sfn , dbt:Tuberculosis , dbt:TOC_limit , ; dbo:thumbnail ; dbp:icd "Z16.24"@en , ""@en ; dbp:meshid "D018088"@en ; dbp:caption "Mycobacterium tuberculosis bacteria seen by microscope"@en ; dbp:field ; dbo:abstract "Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampin. Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB (XDR-TB). Tuberculosis is caused by infection with the bacterium Mycobacterium tuberculosis. Almost one in four people in the world are infected with TB bacteria. Only when the bacteria become active do people become ill with TB. Bacteria become active as a result of anything that can reduce the person's immunity, such as HIV, advancing age, diabetes or other immunocompromising illnesses. TB can usually be treated with a course of four standard, or first-line, anti-TB drugs (i.e., isoniazid, rifampin, pyrazinamide and ethambutol). However, beginning with the first antibiotic treatment for TB in 1943, some strains of the TB bacteria developed resistance to the standard drugs through genetic changes (see mechanisms.) Currently the majority of multidrug-resistant cases of TB are due to one strain of TB bacteria called the Beijing lineage. This process accelerates if incorrect or inadequate treatments are used, leading to the development and spread of multidrug-resistant TB (MDR-TB). Incorrect or inadequate treatment may be due to use of the wrong medications, use of only one medication (standard treatment is at least two drugs), or not taking medication consistently or for the full treatment period (treatment is required for several months). Treatment of MDR-TB requires second-line drugs (i.e., fluoroquinolones, aminoglycosides, and others), which in general are less effective, more toxic and much more expensive than first-line drugs. Treatment schedules for MDR-TB involving fluoroquinolones and aminoglycosides can run for 2 years, compared to the 6 months of first-line drug treatment, and cost over US$100,000. If these second-line drugs are prescribed or taken incorrectly, further resistance can develop leading to XDR-TB. Resistant strains of TB are already present in the population, so MDR-TB can be directly transmitted from an infected person to an uninfected person. In this case a previously untreated person develops a new case of MDR-TB. This is known as primary MDR-TB, and is responsible for up to 75% of cases. Acquired MDR-TB develops when a person with a non-resistant strain of TB is treated inadequately, resulting in the development of antibiotic resistance in the TB bacteria infecting them. These people can in turn infect other people with MDR-TB. MDR-TB caused an estimated 600,000 new TB cases and 240,000 deaths in 2016 and MDR-TB accounts for 4.1% of all new TB cases and 19% of previously treated cases worldwide. Globally, most MDR-TB cases occur in South America, Southern Africa, India, China, and the former Soviet Union. Treatment of MDR-TB requires treatment with second-line drugs, usually four or more anti-TB drugs for a minimum of 6 months, and possibly extending for 18\u201324 months if rifampin resistance has been identified in the specific strain of TB with which the patient has been infected. Under ideal program conditions, MDR-TB cure rates can approach 70%."@en , "\uB2E4\uC81C\uB0B4\uC131 \uACB0\uD575(\u591A\u5291\u8010\u6027\u7D50\u6838, MDR-TB)\uC740 \uAC00\uC7A5 \uAC15\uB825\uD55C \uACB0\uD575 \uCE58\uB8CC\uC81C\uB85C\uC11C 1\uCC28 \uC57D\uC81C\uB85C \uC4F0\uC774\uB294 \uC774\uC18C\uB2C8\uC544\uC9C0\uB4DC(Isoniazid, INH)\uC640 \uB9AC\uD31C\uD53C\uC2E0(Rifampicin, RMP)\uC5D0 \uB0B4\uC131\uC744 \uC9C0\uB2C8\uACE0 \uC788\uB294 \uACB0\uD575\uC744 \uB9D0\uD55C\uB2E4. \uB2E8, \uB2E4\uB978 \uD56D\uACB0\uD575\uC81C\uC758 \uC870\uD569\uC5D0 \uB0B4\uC131\uC774 \uC788\uB2E4\uACE0 \uD558\uB354\uB77C\uB3C4 \uC774\uC18C\uB2C8\uC544\uC9C0\uB4DC\uC640 \uB9AC\uD31C\uD53C\uC2E0\uC5D0 \uB300\uD55C \uB0B4\uC131\uC774 \uC5C6\uC73C\uBA74 \uB2E4\uC81C\uB0B4\uC131 \uACB0\uD575\uC73C\uB85C \uBD84\uB958\uB418\uC9C0 \uC54A\uB294\uB2E4. \uB2E4\uC81C\uB0B4\uC131 \uACB0\uD575\uC740 \uBAA8\uB4E0 \uC57D\uC5D0 \uB4E3\uB294 \uACB0\uD575\uC744 \uCE58\uB8CC\uD558\uB294 \uB3C4\uC911 \uD56D\uC0DD\uC81C\uC758 \uD22C\uC785\uC774 \uC911\uB2E8\uB418\uAC70\uB098 \uCCB4\uB0B4\uC758 \uC57D\uC758 \uC218\uC900\uC774 \uC138\uADE0\uC758 100%\uB97C \uC8FD\uC774\uAE30\uC5D0 \uCDA9\uBD84\uD558\uC9C0 \uC54A\uC744 \uB54C\uC5D0 \uC0DD\uACA8\uB09C\uB2E4. \uADF8 \uC774\uC720\uB85C\uB294 \uC5EC\uB7EC \uAC00\uC9C0\uAC00 \uC788\uB2E4. \uD658\uC790\uB4E4\uC740 \uBCD1\uC138\uAC00 \uD638\uC804\uB418\uC5C8\uB2E4\uACE0 \uC0DD\uAC01\uD558\uACE0 \uD56D\uC0DD\uC81C\uC758 \uD22C\uC785\uC744 \uC911\uB2E8\uD560 \uC218 \uC788\uC73C\uBA70, \uC81C\uACF5\uB418\uB358 \uC57D\uC774 \uB5A8\uC5B4\uC9C0\uAC70\uB098 \uD76C\uADC0\uD574\uC9C8 \uC218 \uC788\uACE0, \uD658\uC790\uAC00 \uAC00\uB054 \uC57D \uBA39\uB294 \uAC83\uC744 \uC78A\uC744 \uC218 \uC788\uB2E4. \uB2E4\uC81C\uB0B4\uC131 \uACB0\uD575\uC740 \uC57D\uC5D0 \uAC10\uC218\uC131\uC774 \uC788\uB294 \uACB0\uD575\uACFC \uAC19\uC740 \uBC29\uBC95\uC73C\uB85C \uC0AC\uB78C\uC5D0\uC11C \uC0AC\uB78C\uC73C\uB85C \uC804\uD30C\uB41C\uB2E4."@ko , "\u0645\u0642\u0627\u0648\u0645\u0629 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0645\u0636\u0627\u062F\u0629 \u0644\u0644\u0633\u0644 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Multi-drug-resistant tuberculosis)\u200F \u0647\u0648 \u0639\u0628\u0627\u0631\u0629 \u0639\u0646 \u0638\u0647\u0648\u0631 \u0633\u0644\u0627\u0644\u0627\u062A \u0644\u0645\u0631\u0636 \u0627\u0644\u0633\u0644 \u0645\u0642\u0627\u0648\u0645\u0629 \u0644\u062C\u0645\u064A\u0639 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0631\u0626\u064A\u0633\u064A\u0629 \u0627\u0644\u0645\u0636\u0627\u062F\u0629 \u0644\u0644\u0633\u0644. \u0648\u062D\u0627\u0644\u0627\u062A \u0627\u0644\u0633\u0644 \u0627\u0644\u0645\u0642\u0627\u0648\u0645 \u0644\u0644\u0623\u062F\u0648\u064A\u0629 \u0646\u0627\u062C\u0645\u0629 \u0639\u0646 \u0627\u0644\u0639\u0644\u0627\u062C \u063A\u064A\u0631 \u0627\u0644\u0645\u0646\u0627\u0633\u0628 \u0623\u0648 \u0627\u0644\u0639\u0644\u0627\u062C \u0627\u0644\u062C\u0632\u0626\u064A\u060C \u0623\u064A \u0639\u0646\u062F\u0645\u0627 \u0644\u0627 \u064A\u0623\u062E\u0630 \u0627\u0644\u0645\u0631\u0636\u0649 \u062C\u0645\u064A\u0639 \u0623\u062F\u0648\u064A\u062A\u0647\u0645 \u0628\u0627\u0646\u062A\u0638\u0627\u0645 \u0623\u062B\u0646\u0627\u0621 \u0627\u0644\u0641\u062A\u0631\u0629 \u0627\u0644\u0645\u062D\u062F\u0651\u062F\u0629 \u0644\u0647\u0645 \u0628\u0633\u0628\u0628 \u0634\u0639\u0648\u0631\u0647\u0645 \u0628\u062A\u062D\u0633\u0646 \u062D\u0627\u0644\u062A\u0647\u0645 \u0627\u0644\u0635\u062D\u064A\u0629\u060C \u0623\u0648 \u0646\u0638\u0631\u0627\u064B \u0644\u0646\u0632\u0648\u0639 \u0627\u0644\u0623\u0637\u0628\u0627\u0621 \u0648\u0627\u0644\u0639\u0627\u0645\u0644\u064A\u0646 \u0627\u0644\u0635\u062D\u064A\u064A\u0646 \u0625\u0644\u0649 \u0648\u0635\u0641 \u062E\u0637\u0637 \u0639\u0644\u0627\u062C\u064A\u0629 \u062E\u0627\u0637\u0626\u0629\u060C \u0623\u0648 \u0646\u0638\u0631\u0627\u064B \u0644\u0639\u062F\u0645 \u0645\u0648\u062B\u0648\u0642\u064A\u0629 \u0627\u0644\u0625\u0645\u062F\u0627\u062F\u0627\u062A \u0627\u0644\u062F\u0648\u0627\u0626\u064A\u0629. \u0648\u064A\u062A\u0645\u062B\u0651\u0644 \u0623\u0643\u062B\u0631 \u0623\u0634\u0643\u0627\u0644 \u00AB\u0627\u0644\u0633\u0644 \u0627\u0644\u0645\u0642\u0627\u0648\u0645\u00BB \u062E\u0637\u0648\u0631\u0629 \u0641\u064A \u0627\u0644\u0633\u0644 \u0627\u0644\u0645\u0642\u0627\u0648\u0645 \u0644\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0645\u062A\u0639\u062F\u0651\u062F\u0629\u060C \u0627\u0644\u0630\u064A \u064A\u064F\u0639\u0631\u0651\u0641 \u0628\u0627\u0644\u0645\u0631\u0636 \u0627\u0644\u0646\u0627\u062C\u0645 \u0639\u0646 \u0627\u0644\u0643\u0641\u064A\u0644\u0629 \u0628\u0645\u0642\u0627\u0648\u0645\u0629 \u0627\u0644\u0625\u064A\u0632\u0648\u0646\u064A\u0627\u0632\u064A\u062F \u0648\u0627\u0644\u0631\u064A\u0641\u0627\u0645\u0628\u064A\u0633\u064A\u0646 \u0639\u0644\u0649 \u0627\u0644\u0623\u0642\u0644\u060C \u0648\u0647\u0645\u0627 \u0623\u0643\u062B\u0631 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0641\u0639\u0627\u0644\u064A\u0629 \u0636\u062F \u0627\u0644\u0633\u0644. \u0648\u0645\u0639\u062F\u0644\u0627\u062A \u0627\u0644\u0633\u0644 \u0627\u0644\u0645\u0642\u0627\u0648\u0645 \u0644\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0645\u062A\u0639\u062F\u0651\u062F\u0629 \u062A\u0631\u062A\u0641\u0639 \u0641\u064A \u0628\u0639\u0636 \u0627\u0644\u0628\u0644\u062F\u0627\u0646\u060C \u0648\u0628\u062E\u0627\u0635\u0629 \u0641\u064A \u0627\u0644\u0627\u062A\u062D\u0627\u062F \u0627\u0644\u0633\u0648\u0641\u064A\u064A\u062A\u064A \u0627\u0644\u0633\u0627\u0628\u0642\u060C \u0648\u062A\u0647\u062F\u0651\u062F \u062C\u0647\u0648\u062F \u0645\u0643\u0627\u0641\u062D\u0629 \u0627\u0644\u0645\u0631\u0636 \u0647\u0646\u0627\u0643. \u0648\u0639\u0644\u0649 \u0627\u0644\u0631\u063A\u0645 \u0645\u0646 \u0627\u0644\u062A\u0645\u0643\u0651\u0646 \u0639\u0645\u0648\u0645\u0627\u064B \u0645\u0646 \u0639\u0644\u0627\u062C \u062D\u0627\u0644\u0627\u062A \u0627\u0644\u0633\u0644 \u0627\u0644\u0645\u0642\u0627\u0648\u0645 \u0644\u0644\u0623\u062F\u0648\u064A\u0629\u060C \u0641\u0625\u0646\u0651 \u062A\u0644\u0643 \u0627\u0644\u062D\u0627\u0644\u0627\u062A \u062A\u0642\u062A\u0636\u064A \u0645\u0639\u0627\u0644\u062C\u0629 \u0643\u064A\u0645\u064A\u0627\u0626\u064A\u0629 \u0645\u0643\u062B\u0651\u0641\u0629 (\u0642\u062F \u062A\u0635\u0644 \u0645\u062F\u0651\u062A\u0647\u0627 \u0625\u0644\u0649 \u0639\u0627\u0645\u064A\u0646) \u0628\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u062E\u0637 \u0627\u0644\u062B\u0627\u0646\u064A \u0627\u0644\u062A\u064A \u062A\u0641\u0648\u0642 \u062A\u0643\u0627\u0644\u064A\u0641\u0647\u0627 \u0641\u064A \u063A\u0627\u0644\u0628 \u0627\u0644\u0623\u062D\u064A\u0627\u0646 \u062A\u0643\u0627\u0644\u064A\u0641 \u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u062E\u0637 \u0627\u0644\u0623\u0648\u0651\u0644\u060C \u0643\u0645\u0627 \u0623\u0646\u0651\u0647\u0627 \u062A\u062A\u0633\u0628\u0651\u0628 \u0641\u064A \u062D\u062F\u0648\u062B \u062A\u0641\u0627\u0639\u0644\u0627\u062A \u0636\u0627\u0626\u0631\u0629 \u0623\u0643\u062B\u0631 \u0648\u062E\u0627\u0645\u0629\u060C \u062D\u062A\u0649 \u0648\u0625\u0646 \u0623\u0645\u0643\u0646 \u062A\u062F\u0628\u064A\u0631\u0647\u0627. \u0648\u0623\u0635\u0628\u062D\u062A \u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u062E\u0637 \u0627\u0644\u062B\u0627\u0646\u064A \u0627\u0644\u0645\u0636\u0627\u062F\u0629 \u0644\u0644\u0633\u0644 \u0648\u0627\u0644\u0645\u0636\u0645\u0648\u0646\u0629 \u0627\u0644\u0646\u0648\u0639\u064A\u0629 \u0645\u062A\u0648\u0627\u0641\u0631\u0629 \u0628\u0623\u0633\u0639\u0627\u0631 \u0645\u0646\u062E\u0641\u0636\u0629 \u0644\u0644\u0645\u0634\u0627\u0631\u064A\u0639 \u0627\u0644\u0645\u0639\u062A\u0645\u062F\u0629 \u0645\u0646 \u0642\u0628\u0644 \u0644\u062C\u0646\u0629 \u0627\u0644\u0636\u0648\u0621 \u0627\u0644\u0623\u062E\u0636\u0631.. \u0648\u064A\u0634\u0643\u0644 \u0638\u0647\u0648\u0631 \u0627\u0644\u0633\u0644 \u0627\u0644\u0634\u062F\u064A\u062F \u0627\u0644\u0645\u0642\u0627\u0648\u0645\u0629 \u0644\u0644\u0623\u062F\u0648\u064A\u0629\u060C \u062E\u0635\u0648\u0635\u0627\u064B \u0641\u064A \u0627\u0644\u0645\u0648\u0627\u0642\u0639 \u0627\u0644\u062A\u064A \u064A\u0643\u0648\u0646 \u0641\u064A\u0647\u0627 \u0645\u0631\u0636\u0649 \u0627\u0644\u0633\u0644 \u0645\u0635\u0627\u0628\u064A\u0646 \u0628\u0641\u064A\u0631\u0648\u0633 \u0627\u0644\u0623\u064A\u062F\u0632 \u0623\u064A\u0636\u0627\u064B\u060C \u062E\u0637\u0631\u0627\u064B \u0643\u0628\u064A\u0631\u0627\u064B \u0639\u0644\u0649 \u062C\u0647\u0648\u062F \u0645\u0643\u0627\u0641\u062D\u0629 \u0627\u0644\u0633\u0644 \u0648\u064A\u0624\u0643\u0651\u062F \u0627\u0644\u062D\u0627\u062C\u0629 \u0627\u0644\u0645\u0627\u0633\u0651\u0629 \u0625\u0644\u0649 \u062A\u0639\u0632\u064A\u0632 \u0623\u0646\u0634\u0637\u0629 \u0645\u0643\u0627\u0641\u062D\u0629 \u0627\u0644\u0633\u0644 \u0627\u0644\u0639\u0627\u062F\u064A \u0648\u062A\u0637\u0628\u064A\u0642 \u062F\u0644\u0627\u0626\u0644 \u0645\u0646\u0638\u0645\u0629 \u0627\u0644\u0635\u062D\u0629 \u0627\u0644\u0639\u0627\u0644\u0645\u064A\u0629 \u0627\u0644\u062C\u062F\u064A\u062F\u0629 \u0644\u062A\u062F\u0628\u064A\u0631 \u062D\u0627\u0644\u0627\u062A \u0627\u0644\u0633\u0644 \u0627\u0644\u0645\u0642\u0627\u0648\u0645 \u0644\u0644\u0623\u062F\u0648\u064A\u0629 \u0645\u0646 \u062E\u0644\u0627\u0644 \u0628\u0631\u0627\u0645\u062C \u0645\u062D\u062F\u0651\u062F\u0629"@ar , "Tuberculose multirresistente (MDR-TB) \u00E9 uma infe\u00E7\u00E3o por tuberculose causada por bact\u00E9rias resistentes ao tratamento com pelo menos dois dos mais fortes medicamentos de primeira linha, isoniazida e rifampicina. Algumas formas de tuberculose s\u00E3o tamb\u00E9m resistentes a medicamentos de segunda linha, sendo nesse caso denominadas tuberculose extensivamente resistente (XDR-TB)."@pt , "Multiresistent tuberkulos \u00E4r en variant av den bakteriella infektionssjukdomen tuberkulos som \u00E4r resistent mot de tv\u00E5 mest effektiva tuberkulosl\u00E4kemedel Isoniazid och Rifampicin. Internationellt anv\u00E4nds ofta begreppet multi-drug-resistant tuberculosis och d\u00E4rf\u00F6r f\u00F6rkortas sjukdomen med MDR-TB. Det finns dessutom ytterligare en form av tuberkulos som \u00E4r resistent mot \u00E4nnu fler l\u00E4kemedel och som betecknas som \u201Dextended multi-drug resistant tuberculosis\u201D eller XDR-TB. Resistens mot tuberkulosl\u00E4kemedel kan \u00E4ven uppst\u00E5 om mediciner inte ordineras eller intas p\u00E5 r\u00E4tt s\u00E4tt, till exempel n\u00E4r patienter inte avslutar en behandling mot vanlig tuberkulos. Resistenser kan ocks\u00E5 uppst\u00E5 n\u00E4r patienter f\u00E5r fel typ av l\u00E4kemedel, l\u00E4kemedel av d\u00E5lig kvalitet, fel dos eller inte behandlas tillr\u00E4ckligt l\u00E4nge. Precis som tuberkulos smittas den multiresistenta formen n\u00E4r en sjuk person hostar eller nyser genom sm\u00E5 droppar i luften. Patienter som utvecklar multiresistent tuberkulos kan ocks\u00E5 direkt smitta andra m\u00E4nniskor."@sv , "\u591A\u5264\u8010\u6027\u80BA\u7D50\u6838\uFF08\u305F\u3056\u3044\u305F\u3044\u305B\u3044\u306F\u3044\u3051\u3063\u304B\u304F\u3001MDR\uFF09\u3068\u306F\u3001\u80BA\u7D50\u6838\u306E\u3046\u3061\u3001\u6CBB\u7642\u3068\u3057\u3066\u4F7F\u308F\u308C\u308B\u6297\u751F\u7269\u8CEA\u306E\u30A4\u30BD\u30CB\u30A2\u30B8\u30C9\u3084\u30EA\u30D5\u30A1\u30F3\u30D4\u30B7\u30F3\u306A\u3069\u306B\u85AC\u5264\u8010\u6027\u3092\u6301\u3063\u305F\u72B6\u614B\u3092\u3044\u3046\u3002"@ja , "Se conoce como tuberculosis multidrogorresistente (TB-MDR) es aquella infecci\u00F3n por Mycobacterium tuberculosis por aquellas cepas de esta bacteria resistentes a los siguientes dos : \n* Isoniacida \n* Rifampicina Los primeros casos fueron detectados en brotes en los Estados Unidos y Argentina a fines de la d\u00E9cada de los 80s. Se requiere f\u00E1rmacos de segunda l\u00EDnea que son menos eficaces y con efectos adversos m\u00E1s graves. Se ha reportado una asociaci\u00F3n de casos de TB-MDR con la infecci\u00F3n por VIH y algunos estados de inmunosupresi\u00F3n."@es ; dbo:meshId "D018088" . @prefix prov: . dbr:Multidrug-resistant_tuberculosis prov:wasDerivedFrom . @prefix xsd: . dbr:Multidrug-resistant_tuberculosis dbo:wikiPageLength "70616"^^xsd:nonNegativeInteger ; dbo:icd10 "Z16.24" . @prefix wikipedia-en: . dbr:Multidrug-resistant_tuberculosis foaf:isPrimaryTopicOf wikipedia-en:Multidrug-resistant_tuberculosis .